Clinical Trial Update: [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating [18F]Fluciclatide-PET in combination with Pazopanib and Paclitaxel for ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pazopanib (Pazopanib)
• [18F]Fluciclatide-PET (fluciclatide radiotracer)

Snippet

Sponsor: Imperial College London | Conditions: Ovarian Neoplasm | Phase 1 | Status: COMPLETED